Search
Dapagliflozin
go.drugbank.com/drugs/DB06292ApprovedInvestigationalDapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. … [A261596] When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria
Mixtures: XIGDUO® XR 10MG/1000MG TABLETAS RECUBIERTAS DE LIBERACION PROLONGADA, XIGDUO® XR 10MG/1000MG TABLETAS RECUBIERTAS DE LIBERACION PROLONGADAMuplestim
go.drugbank.com/drugs/DB12431InvestigationalMuplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL
Ribavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalAccording to 2017 American Association for the Study of Liver Diseases (AASLD) and 2015 consensus guidelines from the Canadian Association for the Study of the Liver (CASL), ribavirin is typically used … Additionally, including ribavirin in the regimen can increase the risk of anemia.
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Tegafur
go.drugbank.com/drugs/DB09256ApprovedInvestigationalTegafur is usually given in combination with other drugs that enhance the bioavailability of the 5-FU by blocking the enzyme responsible for its degradation, or serves to limit the toxicity of 5-FU by … When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the
Mixtures: TS-ONE CAPSULE 20, TS-ONE CAPSULE 20International brands: TS-1, NKS-1 TGlucosamine
go.drugbank.com/drugs/DB01296Approved[A231894,A232289] It is currently not approved as a prescription product by the FDA, but is widely available over the counter. … [A232289] Treatment with chondroprotective drugs, such as glucosamine sulfate may offer additional benefits to nonsteroidal anti-inflammatory drugs treating the painful symptoms of OA.
Mixtures: Melittin Joint Soothing Ge, FLEXURE®CAPSULA DE GELATINAProducts: GLUCOSAMINA E-PHARMA TRENTO, GLUCOSAMINA (SULFATO DE GLUCOSAMINA 250MG) NATURAL SYSTEMSMifamurtide
go.drugbank.com/drugs/DB13615ApprovedInvestigationalIn a large, randomized, open-label, multicenter, phase III trial, the treatment of mifamurtide in conjunction with three- or four-drug combination chemotherapy (doxorubicin, cisplatin, and high-dose methotrexate … The overall result of MDP recognition leads to the production of proinflammatory cytokines and promotion of bactericidal and tumoricidal effects [A31745].
Capecitabine
go.drugbank.com/drugs/DB01101ApprovedInvestigationalCapecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. … Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers.
Phenylalanine
go.drugbank.com/drugs/DB00120ApprovedInvestigationalNutraceuticalPhenylalanine is an essential aromatic amino acid that is a precursor of melanin, dopamine, noradrenalin (norepinephrine), and thyroxine.
Mixtures: Clinimix E, Clinimix EEmtricitabine
go.drugbank.com/drugs/DB00879ApprovedInvestigational[L9019] The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.[L9019] Emtricitabine was granted FDA approval on 2 July 2003.[L9019] … Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults[L9019] or combined with [tenofovir alafenamide] for the prevention of HIV-1 infection
Mixtures: Emtricitabine/ten Ofovir Disoproxil Mylan, Emtricitabine/ten Ofovir Disoproxil MylanCategories: Antivirals used in combination for the treatment of HIV infectionsNerofe
go.drugbank.com/drugs/DB14786InvestigationalNerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).